Biophan Technologies Research Note Issued by Investrend Research Affiliate Beacon Equity Research Regarding Cardiovascular Division.NEW YORK -- (Investrend Research Syndicate) A new research note on Biophan Technologies (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ) has been issued by Beacon Equity Research Senior Analyst, Shailesh Dhuri. The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com In the report, Mr. Dhuri writes, "Biophan has recently entered into a comprehensive agreement with a leading biomedical manufacturer, Boston Scientific Corporation (NYSE NYSE See: New York Stock Exchange : BSX), on an equity investment and technology license... Biophan has further announced the acquisition of a substantial minority interest with the right to acquire a controlling interest in Myotech, LLC. In addition, this deal provides for Biophan to control the development, regulatory approval and marketing of Myotech's MYO-VAD(TM) cardiac assist technology. According to the American Heart Association American Heart Association (AHA), n.pr a national voluntary health agency that has the goal of increasing public and medical awareness of cardiovascular diseases and stroke, and thereby reducing the number of associated deaths and disabilities. , approximately five million Americans have some form of congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , with some 500,000 new cases occurring every year. The critical cases, estimated at 50,000, may require heart transplants. This represents one group of potential beneficiaries from cardiac assist devices... The existing VAD (Value Added Dealer) Same as VAR. takes 45 minutes or more to install in a heart. However, Biophan claims that its DMVA DMVA Department of Military and Veterans Affairs can be installed in three minutes, with minimal invasive surgery. Thus, this is a critical advantage of DMVA." Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. Institute's (CFAI) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow. Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research has been compensated a total of $29,000 by Biophan Technologies for a one-year enrollment in its research program. Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes,. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. Anyone interested in receiving alerts regarding Biophan Technologies research should email contact@investrend.com with "BIPH" in the subject line. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion